Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

2.

Error occurred: cannot get document summary

PMID:
31611798

3.

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.

Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J.

Int J Oncol. 2014 Sep;45(3):1027-35. doi: 10.3892/ijo.2014.2505. Epub 2014 Jun 19.

4.

COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.

Li J, Zhou Y, Wang H, Gao Y, Li L, Hwang SH, Ji X, Hammock BD.

Oncotarget. 2017 Sep 15;8(50):87353-87363. doi: 10.18632/oncotarget.20928. eCollection 2017 Oct 20.

5.

Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.

Gartung A, Yang J, Sukhatme VP, Bielenberg DR, Fernandes D, Chang J, Schmidt BA, Hwang SH, Zurakowski D, Huang S, Kieran MW, Hammock BD, Panigrahy D.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.

6.

A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.

Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD.

Prostaglandins Other Lipid Mediat. 2016 Sep;125:40-7. doi: 10.1016/j.prostaglandins.2016.07.003. Epub 2016 Jul 16.

7.

Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.

Lakkappa N, Krishnamurthy PT, Yamjala K, Hwang SH, Hammock BD, Babu B.

J Pharm Biomed Anal. 2018 Feb 5;149:457-464. doi: 10.1016/j.jpba.2017.11.043. Epub 2017 Nov 16.

8.

Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.

Grivas PD, Day KC, Karatsinides A, Paul A, Shakir N, Owainati I, Liebert M, Kunju LP, Thomas D, Hussain M, Day ML.

Mol Med. 2013 Nov 8;19:367-76. doi: 10.2119/molmed.2013.00108.

9.

1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.

Ma Y, Yu WD, Trump DL, Johnson CS.

Cancer. 2010 Jul 1;116(13):3294-303. doi: 10.1002/cncr.25059.

10.

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.

Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.

Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062.

11.

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.

da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET, Salvadori DM.

Exp Biol Med (Maywood). 2010 Jul;235(7):814-24. doi: 10.1258/ebm.2010.009322.

PMID:
20558835
12.

Platinum compounds in the treatment of advanced breast cancer.

Martín M.

Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209. Review.

PMID:
11899413
13.

Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.

Park BH, Lim JE, Jeon HG, Seo SI, Lee HM, Choi HY, Jeon SS, Jeong BC.

Oncotarget. 2016 Sep 27;7(39):63870-63886. doi: 10.18632/oncotarget.11563.

14.

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP.

Urol Oncol. 2009 Jul-Aug;27(4):391-9. doi: 10.1016/j.urolonc.2008.03.017. Epub 2008 Jun 4.

PMID:
18534874
15.

CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.

Gao F, Wang X, Chen S, Xu T, Wang X, Shen Y, Dong F, Zhong S, Shen Z.

Oncol Rep. 2018 Nov;40(5):2445-2454. doi: 10.3892/or.2018.6641. Epub 2018 Aug 10.

16.

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.

Wang Y, Huang F, Cai H, Wu Y, He G, Tan WS.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1827-37. doi: 10.1007/s00432-010-0841-8. Epub 2010 Mar 7.

PMID:
20213096
17.

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.

Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, Qi L, Zu X.

J Exp Clin Cancer Res. 2016 Jan 6;35:2. doi: 10.1186/s13046-015-0282-y.

18.

Emetine dihydrochloride: a novel therapy for bladder cancer.

Foreman KE, Jesse JN 3rd, Kuo PC, Gupta GN.

J Urol. 2014 Feb;191(2):502-9. doi: 10.1016/j.juro.2013.09.014. Epub 2013 Sep 14.

PMID:
24045224
19.

Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.

Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW.

Mol Cancer Ther. 2006 Feb;5(2):329-36.

20.

In vitro and in vivo experiments on electrochemotherapy for bladder cancer.

Vásquez JL, Ibsen P, Lindberg H, Gehl J.

J Urol. 2015 Mar;193(3):1009-15. doi: 10.1016/j.juro.2014.09.039. Epub 2014 Sep 19.

PMID:
25245485

Supplemental Content

Support Center